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Abstract
Introduction: Extremely high glucose concentrations have been shown to interfere with creatinine assays especially with Jaffe method in peri-
toneal dialysate. Because diabetes is the fastest growing chronic disease in the world, laboratories study with varying glucose concentrations. We 
investigated whether different levels of glucose spiked in serum interfere with 21 routine chemistry and thyroid assays at glucose concentrations 
between 17-51 mmol/L.
Materials and methods: Baseline (group I) serum pool with glucose concentration of 5.55 (5.44-5.61) mmol/L was prepared from patient sera. 
Spiking with 20% dextrose solution, sample groups were obtained with glucose concentrations: 17.09, 34.52, and 50.95 mmol/L (group II, III, IV, 
respectively). Total of 21 biochemistry analytes and thyroid tests were studied on Abbott c8000 and i2000sr with commercial reagents. Bias from 
baseline value was checked statistically and clinically. 
Results: Creatinine increased significantly by 8.74%, 31.66%, 55.31% at groups II, III, IV, respectively with P values of < 0.001. At the median glucose 
concentration of 50.95 mmol/L, calcium, albumin, chloride and FT4 biased significantly clinically (-0.85%, 1.63%, 0.65%, 7.4% with P values 0.138, 
0.214, 0.004, < 0.001, respectively). Remaining assays were free of interference.
Conclusion: Among the numerous biochemical parameters studied, only a few parameters are affected by dramatically increased glucose concen-
tration. The creatinine measurements obtained in human sera with the Jaffe alkaline method at high glucose concentrations should be interpreted 
with caution. Other tests that were affected with extremely high glucose concentrations were calcium, albumin, chloride and FT4, hence results 
should be taken into consideration in patients with poor diabetic control.  
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According to the World Diabetes Foundation, dia-
betes is the world’s fastest growing chronic dis-
ease that affects 6.4% of the world’s adult popula-
tion (1), hence laboratories study with high glu-
cose levels at varying concentrations. However, 
extremely high glucose concentrations have been 
shown to interfere with creatinine assays, especial-
ly with the Jaffe method in peritoneal dialysate (2-
5).
The accuracy of the clinical laboratory tests is im-
portant for patient care, and control of the whole 
testing process is the responsibility of laboratory 
professionals. Though the errors in the analytical 
phase are under strict control by the improved 
technology and control materials, body fluid com-
pounds are known to interfere with some analyti-
cal reaction steps that are not yet solved by the 
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manufacturers. The most common analytical assay 
method affected in clinical chemistry is the Jaffe’s 
reaction for creatinine determination. 
The interference is defined as “the effect of a sub-
stance present in the sample that alters the correct 
value of the result, usually expressed as concentra-
tion or activity, for an analyte” (6). The major en-
dogenous substances that interfere with the labo-
ratory analyses are hemoglobin, bilirubin, and li-
pids (6-8).
Glucose is cited as an endogenous interferent fac-
tor for creatinine assay with the Jaffe method in 
several articles (9,10) especially in the peritoneal 
dialysate and this reaction is known to be affected 
by bilirubin, hemoglobin, lipid, and protein (11,12). 
Studies have been published comparing the Jaffe 
and enzymatic methods about the reliability for 
creatinine determination in serum and body fluids, 
however there is no consensus.
Because the magnitude of interference varies from 
method to method and according to the concen-
tration of the interferent (11,13), we aimed to ex-
periment the interfering effect of glucose at differ-
ent levels on routine biochemistry analytes and 
thyroid function tests in human sera. 
Materials and methods
Subjects
This study was conducted in the clinical laboratory 
of Abant Izzet Baysal University, Bolu, Turkey in 
2015. We assessed the study with consecutive se-
rum samples collected for routine clinical care. No 
additional blood was taken from patients. The 
study protocol was conducted in accordance with 
the ethical standards of the institutional commit-
tee on human experimentation and with the Hel-
sinki Declaration. The study was approved by the 
review board of Ordu University, Turkey with the 
project number: 16 /13.April.2015. 
Study protocol
Fasting venous blood was collected in the morn-
ing into plastic evacuated tubes (BD Vacutainer 
SST II Advance, Becton- Dickinson, Franklin Lakes, 
New Jersey, USA). All were left in the upright posi-
tion for 30 min at room temperature for complete 
clot formation, and then centrifuged at 2000 x g 
for 10 minutes. Sera of each blood were checked 
visually for hemolysis, lipemia and bilirubinemia. 
Totally 16 serum pools were prepared with glu-
cose concentration of 5.55 (5.44 - 5.61) mmol/L as 
baseline (group I). Remaining sera were aliquoted 
into four tubes which were spiked with a dextrose 
solution (20% dextrose in distilled water, Neofleks, 
Turktıpsan, Ankara, Turkey) to obtain final median 
glucose concentrations of 17.09 mmol/L (990 μL 
sera + 10 μL dextrose), 34.52 mmol/L (975 μL sera 
+ 25 μL dextrose), 50.95 mmol/L (960 μL sera + 40 
uL dextrose). 
The following parameters were studied:
•	 Routine parameters: glucose, urea nitrogen 
(BUN), creatinine, calcium, direct and total bili-
rubin, magnesium, phosphorus, uric acid, albu-
min, total protein, CRP, triglycerides, cholester-
ol, ALP, ALT, AST, GGT, LD, sodium, potassium, 
chloride.
•	 Immune parameters: TSH, FT3, free thyroxine (FT4). 
Routine biochemistry tests were studied on an Ab-
bott Architect c8000 autoanalyzer (Abbott Labo-
ratories, IL, USA), immunoassays were studied on 
the Architect i2000sr immunochemistry system 
(Abbott Laboratories, IL, USA) with commercial re-
agents. All measurements were performed on the 
same day. The analytical methods used are listed 
in Table 1. 
Intra-assay CV’s were performed with three levels 
of control materials [Clin Chem: Multichem S Plus, 
lot: 14005140 (Technopath, Tipperary, Ireland)], 
CRP: Archem Romatoid control, lot: 1311120 
(Archem Diagnostics, Istanbul, Turkey), immunoas-
say: Technopath Multiimmunoassay Control lot: 
33709140 (Technopath, Tipperary, Ireland). Intra-
assay variation was assessed from 20 determina-
tions at two-or three levels on the same day. The 
between run quality control data and methods are 
listed in Table 1.
Statistical analysis
The dilutional bias correction for the added vol-
ume of the dextrose solution was performed with 
http://dx.doi.org/10.11613/BM.2016.004 Biochemia Medica 2016;26(1):53–60 
  55
Çuhadar S. et al. Glucose interference study 
Analyte (units) Method Level 1 CV1 (%) Level 2 CV2 (%) Level 3 CV3 (%)
ALT (U/L) UV without P5P 29.4 0.1 110.7 0.43 233.5 0.24
Albumin (g/L) Bromcresol green 28 1.3 44.2 1.2 55.6 0.72
ALP (U/L) PNP 66 1.4 184 0.8 370 0.3
AST (U/L) UV without P5P 44.85 0.1 135 0.5 241.5 0.45
Bilirubin, direct (µmol/L) Diazotization 7.18 0.1 19.84 1.06 53.18 0.4
Bilirubin, total (µmol/L) Diazonium ion 14.88 0.87 37.11 0.32 108.93 0.21
Calcium (mmol/L) Arsenazo III 1.52 1.35 2.37 0.93 3.23 0.7
Chloride (mmol/L) Ion selective electrode 84 0.1 93.7 0.1 105.4 0.1
Cholesterol (mmol/L) CHOD-PAP 2.63 0.87 4.11 0.1 6.30 0.34
CRP (mg/L) Immunoturbidimetry 177 1.45 460 0.98
Creatinine (µmol/L) Alkaline picrate 58.34 1.31 183.87 1.31 566.64 0.99
Glucose (mmol/L) Hexokinase 2.86 0.99 7.03 1.17 16.53 0.91
GGT (U/L) γ-glutamyl-carboxy nitroanilide 25.45 0.1 76.5 0.77 152.5 0.7
LD (U/L) Lactate-pyruvate, UV 107.65 5.95 223.5 1.7 476 1.07
Magnesium (mmol/L) Enzymatic 0.54 3.1 1.08 2.04 1.80 0.84
Phosphorus (mmol/L) Phosphomolybdate 0.69 2.32 1.25 1.06 2.27 0.1
Potassium (mmol/L) Ion selective electrode 2.51 0.1 3.89 1.17 6.74 0.1
Protein,
total (g/L) Biuret 46.2 0.96 67.9 0.65 87.6 0.5
Sodium (mmol/L) Ion selective electrode 119.5 0.37 143 0.31 157.5 0.52
Triglyceride (mmol/L) GPO-PAP 0.63 0.93 1.44 0.84 2.37 0.76
Urea (mmol/L) Urease, UV 3.06 4.26 13.93 1.04 22.93 1.26
Uric acid (µmol/L) Uricase, PAP 142.16 1.96 359.85 0.76 475.84 0.7
FT3 (pg/mL) Chemiluminescence 2.65 2.04 4.21 2.05 9.67 2.88
FT4 (ng/dL) Chemiluminescence 0.62 3.27 1.68 3.56 2.9 3.77
TSH (µU/mL) Chemiluminescence 0.09 2.39 3.58 1.28 18.9 2.76
Immune parameters (TSH, FT3 and FT4) were analyzed on Abbott Architect i2000, remaining (routine parameters) were studied on 
Abbott Architect c8000.
Intra-assay variation, assessed from 20 determinations, was measured on a single assay. 
ALP - alkaline phosphatase; ALT - alanine aminotransferase; AST - aspartate aminotransferase; CHOD-PAP - cholesterol oxidase-phenol 
aminophenazone; CRP - C reactive protein; FT3 - free triiodothyronine; FT4 - free thyroxine; GGT - gamma-glutamyl transferase; 
GPO-PAP - glycerol-3-phosphate oxidase-phenol aminophenazone; LD - lactate dehydrogenase; PAP - phenol aminophenazone; P5P 
- Pyridoxyl-5-Phosphate; PNP - p-Nitrophenyl phosphate; TSH - thyroid stimulating hormone. 
Table 1. Methods and intra-assay coefficient of variations. 
the result multiplied by 0.01, 0.025, 0.04, respec-
tively, for group II, III and IV then by adding to the 
value obtained. 
For samples supplemented with the interfering ef-
fect of glucose, the clinical significance was calcu-
lated as: [(CX-C1) / C1)] × 100; where C1 represents 
the median of the baseline sample and CX repre-
sents the median of the experimented sample.
The criterion for the presence of a bias specific for 
that analyte was defined according to the desira-
ble bias updated in 2014 (14). Results are expressed 
as a median (min-max) as the number of subjects 
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were small (N = 16). Interference effects were 
checked by Wilcoxon signed rank test for paired 
data when concentrations were compared with 
baseline. Bonferroni correction was applied and P 
value of 0.05 / 4 = 0.0125 was considered as signifi-
cant. All statistical analyses were carried out with 
SPSS version 15.0 (SPSS, Chicago, IL, USA).
Results
The interference of glucose on creatinine showed 
an increasing trend with increasing glucose con-
centrations. The creatinine bias percentages at 
median glucose concentrations of 17.09, 34.52, and 
50.95 mmol/L in serum pools were 8.74%, 31.66%, 
and 55.31%, respectively, with P value of < 0.001 at 
each level (Figure 1, Table 2). 
Serum calcium concentration  decreased, albumin, 
chloride and FT4 concentration increased with 
percent biases of -0.85%, 1.63%, 0.65%, 7.4% at 
glucose concentrations of 50.95 mmol/L where 
the interferences were clinically significant with P 
values 0.138, 0.214, 0.004, and < 0.001, respectively.
Although triglycerides, BUN and direct bilirubin bi-
ased at different levels of glucose significantly sta-
tistically, none of them reached to a clinical signifi-
cance. Remaining parameters AST, ALT, ALP, LD, 
GGT, total bilirubin, cholesterol, phosphorus, mag-
nesium, sodium, potassium, total protein, uric acid, 
CRP, TSH, FT3 were detected as free of interference 
at each level of glucose in sera. 
Discussion
This study aimed to assess the influence of glucose 
on routine chemistry and thyroid assays in serum 
by high glucose concentrations. As a result, a nu-
merous biochemistry parameters were found as 
unaffected. All the same we observed the interfer-
ence on creatinine measurement with the Jaffe ki-
netic method at high glucose concentrations. Ad-
ditionally, calcium, albumin, chloride, and FT4 
measurements interfered with glucose at 50.95 
mmol/L.  
Glucose has been reported to interfere with the 
measurement of creatinine concentrations in 
some creatinine assays where mostly the Jaffe 
method (3-5,9). The kinetic Jaffe reaction is still the 
predominantly used assay method in creatinine 
determination where creatinine reacts with picric 
acid to form a yellow-red creatinine-picrate com-
plex in an alkaline pH. The rate of increase of the 
complex formation in absorbance at 500 nm is di-
rectly proportional to creatinine concentration in 
the sample. Many substances interfere with this 
assay that positive as well as negative biases have 
been demonstrated with bilirubin, dopamin, glu-
cose, drugs and ketoacids (11). The interfering ef-
fect is between the reaction creatinine and alka-
line picrate (15). Bilirubin interferes this assay with 
the same reaction under alkaline conditions which 
is oxidized to biliverdin causing a decrease in ab-
sorbance at 520 nm that result in false lower creati-
nine concentrations (15).
Glucose forms an interfering chromogen with pic-
rate where that chromogen has a smaller absorp-



















Figure 1. Interferogram for glucose and measured parameters: 
albumin, creatinine, calcium, chloride and free thyroxine (FT4).
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Table 2. Median values of the analytes and glucose concentrations for each group, % bias of analyte concentrations in comparison to 
baseline values and desirable bias (14). 
Glucose (mmol/L)

















ALT (U/L) 18 (9-32) 18 (9-31) 17 (9-32) 19 (9-31)
P 0.649 0.551 0.570
% 0 -5.5 5.5 ± 11.48
Albumin (g/L) 43.0 (31.0-46.0) 43.4 (30.3-46.5) 43.6 (30.8-46.1) 43.7 (31.2-46.8)
P 0.604 0.004 0.214
% 0.93 1.40 1.63 ± 1.43
ALP (U/L) 75 (51-116) 76 (50-116) 75 (51-117) 75 (51-115)
P 0.959 0.642 0.088
% 1.33 0 0 ± 6.72
AST (U/L) 19 (12-25) 18 (11-25) 18 (12-26) 18 (11-25)
P 0.959 0.337 0.876
% -5.26 -5.26 -5.26 ± 6.54
Bilirubin, direct (µmol/L) 3.68 (1.71-5.81) 3.63 (1.71-5.81) 3.68 (1.88-5.81) 3.82 (1.71-5.99)
P 0.121 0.044 0.008
% -1.4 0 3.8 ± 14.2
Bilirubin, total (µmol/L) 10.94 (4.96-19.15) 10.97 (4.96-19.15) 10.78 (5.30-19.15) 11.12 (4.96-19.15)
P 0.756 0.717 0.642
% 0.27 -1.46 1.65 ± 8.95
Calcium (mmol/L) 2.36 (2.25-2.65) 2.37 (2.20-2.55) 2.36 (2.18-2.56) 2.34 (2.21-2.55)
P 0.042 0.053 0.138
% 0.42 0 -0.85 ± 0.82
Chloride (mmol/L) 108.5 (104.0-112.0) 108.9 (104.0-112.1) 108.7 (104.6-111.7) 109.2 (105.0-112.3)
P 0.006 0.015 0.004
% 0.37 0.18 0.65 ± 0.5
Cholesterol (mmol/L) 4.94 (3.74-6.00) 4.94 (3.73-6.04) 4.92 (3.70-6.02) 4.96 (3.76-6.03)
P 0.234 0.865 0.816
% 0 -0.4 0.4 ± 4.1
CRP (mg/L) 30.6 (22.1-40.5) 30.2 (21.6-41.2) 30.1 (21.9-42.3) 29.9 (21.0-42.0)
P 0.433 0.532 0.932
% -1.3 -1.7 -2.3 ± 21.8
Creatinine (µmol/L) 69.8 (63.7-119.3) 75.9 (71.6-131.0) 91.9 (83.1-150.3) 108.5 (99.0-165.3)
P < 0.001 < 0.001 < 0.001
% 8.74 31.66 55.31 ± 3.96
FT3 (pg/mL) 3.06 (2.21-4.05) 3.01 (2.16-4.12) 3.01 (2.19-4.23) 2.99 (2.10-4.20)
P 0.408 0.469 0.796
% -1.6 -1.6 -2.3 ± 4.8
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Glucose (mmol/L)









FT4 (ng/dL) 1.08 (0.82-1.37) 1.09 (0.81-1.42) 1.10 (0.85-1.43) 1.16 (0.93-1.47)
P 0.286 < 0.001 < 0.001
% 0.9 1.9 7.4 ± 3.3
GGT (U/L) 20 (11-45) 20 (11-44) 19 (11-45) 19 (10-46)
P 0.234 0.679 0.325
% 0 -5 -5 ± 11.06
LD (U/L) 179 (166-339) 176 (167-338) 181 (164-341) 178 (165-345)
P 0.301 0.438 0.660
% -1.7 1.1 -0.6 ± 4.3
Magnesium (mmol/L) 0.86 (0.77-0.91) 0.85 (0.78-0.93) 0.85 (0.78-0.92) 0.86 (0.77-0.94)
P 1.000 0.836 0.679
% -1.2 -1.2 0 ± 1.8
Phosphorus (mmol/L) 1.24 (0.97-1.45) 1.22 (1.01-1.47) 1.23 (1.00-1.46) 1.24 (1.01-1.48)
P 0.679 0.776 0.534
% -1.61 -0.81 0 ± 3.38
Potassium (mmol/L) 4.60 (3.90-5.20) 4.60 (3.94-5.15) 4.61 (3.90-5.12) 4.63 (3.95-5.20)
P 0.043 0.276 0.733
% 0 0.22 0.65 ± 1.81
Protein, total (g/L) 72.5 (55.0-77.0) 72.4 (54.5-75.8) 72.8 (55.4-75.8) 72.8 (54.1-77.0)
P 0.438 0.379 0.255
% -0.14 0.41 0.41 ± 1.36
Sodium (mmol/L) 141.1 (139-143) 141.4 (138-143) 141.4 (138-144) 141.4 (138-144)
P 0.677 0.299 0.406
% 0.21 0.21 0.21 ± 0.23
TSH (mIU/L) 1.06 (0.51-6.98) 1.05 (0.51-6.86) 1.05 (0.52-7.02) 1.07 (0.52-6.45)
P 0.605 1.000 0.605
% -0.94 -0.94 0.94 ± 7.8
Triglyceride (mmol/L) 1.45 (0.87-2.47) 1.48 (0.86-2.48) 1.48 (0.86-2.51) 1.47 (0.87-2.50)
P 0.004 0.019 0.066
% 2.07 2.07 1.38 ± 9.57
Urea nitrogen (mmol/L) 5.18 (3.57-7.85) 5.23 (3.61-8.29) 5.12 (3.66-8.05) 5.20 (3.71-8.17)
P 0.005 0.569 0.698
% 0.97 -1.16 0.39 ± 5.57
Uric acid (µmol/L) 303 (226-405) 300 (229-403) 302 (226-396) 300 (223-408)
P 0.059 0.047 0.649
% -0.99 -0.33 -0.99 ± 4.87
Values in brackets represent medians (min-max). 
ALP - alkaline phosphatase; ALT - alanine aminotransferase; AST - aspartate aminotransferase; CRP – C reactive protein; FT3 - free 
triiodothyronine; FT4 - free thyroxine; GGT - gamma-glutamyl transferase; LD - lactate dehydrogenase; TSH - thyroid stimulating 
hormone. 
Wilcoxon signed rank test was used to compare the repeated measures with a post-hoc Bonferroni correction. P < 0.0125 values are 
considered statistically significant. Results higher than desirable bias and statistically significant differences are marked in bold.
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insignificant at physiological concentrations of 
glucose (4), but in continuous ambulatory perito-
neal dialysis (CAPD) fluid containing very high glu-
cose concentrations, this interference becomes 
clinically significant. At constant creatinine con-
centrations, interference increased with the in-
creasing glucose concentrations similar to our 
study (4,13).
Interference of creatinine measurement in CAPD 
fluid was found as dependent both on glucose 
and creatinine concentrations. At constant glucose 
concentrations, the higher the creatinine concen-
tration, the more target chromogen would be 
formed hence would reduce the formation of glu-
cose-picrate interfering chromogen. That compe-
tition of creatinine and glucose for the limited 
amount of picrate would reduce the interference 
in alkaline picrate reaction. Conversely, in the en-
zymatic method, at constant glucose concentra-
tion, the magnitude of interference was higher at 
higher creatinine concentrations (4).   
Concerning creatinine measurement in plasma 
and urine, both the Jaffe’s reaction and the enzy-
matic method gave acceptable results (3,5). How-
ever in dialysate fluids there is no consensus. In the 
study by Ferry et al. (5), both methods gave false 
higher creatinine concentrations at high concen-
trations of glucose (≥ 1.36%). They proposed the 
high performance liquid chromatography (HPLC) 
method as a reference to overcome that interfer-
ence or to use the correction factor when used the 
Jaffe method. However Larpent and Verger (3) ob-
served bias only with the Jaffe method in perito-
neal dialysis solutions, hence the enzymatic meth-
od was recommended instead where the glucose 
interference appeared negligible like a newer 
study by Sjøland and Marcher (16). Also, glucose 
degradation product 5-hydroxymethyl furfural 
was detected as interfered with the Jaffe’s reaction 
more than glucose, but not with the measurement 
of enzymatic creatinine (3).
The established correction equations to predict 
the correct creatinine value to account for the glu-
cose interference was found as failed due to inter-
ference effect of calcium chloride, a constituent of 
the peritoneal dialysate (9,10). Calcium (1.75 
mmol/L) enhanced the interference caused by 
glucose at 236 mmol/L in Jaffe creatinine method. 
It was considered that calcium acted as a cofactor 
in the reduction of alkaline picric acid to pictamate 
in proportion to the calcium concentration (9). 
Although several correction formulae for the glu-
cose interference of creatinine measurement have 
been proposed, it has been considered that differ-
ent analytical systems require specific formulae; 
besides multifactorial interference that was deter-
mined in CAPD solution requires multiple correc-
tion formulae which are impractical (4). 
To our knowledge, no interference effect of glu-
cose was reported for calcium, albumin, chloride 
and FT4 assays with the methods we used or oth-
ers. In this study, use of Arsenazo methods of cal-
cium measurement yielded negative bias when in-
terfered with extremely high glucose at normal 
calcium levels. For FT4 assay, heterophile antibod-
ies are considered to be the interference factors 
for some immonoassays (17). Use of chemilumi-
nescence microparticle immunoassay method 
with a two-step design in which the patient serum 
and labelled FT4 are separated in a wash step. FT4 
concentrations were biased positively at glucose 
concentration of 50.95 mmol/L with normal FT4 
values.
There are some limitations to our study. As a limi-
tation, the number of samples included was rela-
tively small. Measurements were performed with 
the defined analyzer with its original reagents; 
therefore, these results are not universal. Addition-
ally, the patient samples may contain various inter-
fering substances that may be responsible for a 
given interference that is unknown because of the 
selected parameters. Our data do not identify the 
origin of the bias given for albumin, chloride, cal-
cium, FT4 and also creatinine.
In conclusion, among the numerous biochemical 
parameters studied, only a few parameters are af-
fected by dramatically increased glucose concen-
tration. The creatinine measurements obtained in 
human sera with the Jaffe alkaline method at high 
glucose concentrations should be interpreted with 
caution as not yet solved by the manufacturers. 
Moreover, the interference was observed with nor-
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mal creatinine concentrations that should be un-
derlined. Calcium, albumin, chloride and FT4 as-
says need to be interpreted with caution in diabet-
ics with poor glycemic control.
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